Dynasty Wealth Management LLC Purchases New Position in Ionis Pharmaceuticals, Inc. $IONS

Dynasty Wealth Management LLC acquired a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 14,341 shares of the company’s stock, valued at approximately $938,000.

A number of other large investors have also modified their holdings of the stock. CWM LLC boosted its holdings in Ionis Pharmaceuticals by 7.3% in the 3rd quarter. CWM LLC now owns 2,488 shares of the company’s stock worth $163,000 after acquiring an additional 170 shares during the period. Steigerwald Gordon & Koch Inc. purchased a new stake in Ionis Pharmaceuticals during the 3rd quarter worth $25,000. Mather Group LLC. acquired a new position in Ionis Pharmaceuticals in the 3rd quarter worth $27,000. GAMMA Investing LLC increased its position in shares of Ionis Pharmaceuticals by 44.2% during the third quarter. GAMMA Investing LLC now owns 1,341 shares of the company’s stock worth $88,000 after acquiring an additional 411 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its stake in Ionis Pharmaceuticals by 3.9% during the 2nd quarter. PNC Financial Services Group Inc. now owns 11,411 shares of the company’s stock valued at $451,000 after purchasing an additional 424 shares in the last quarter. Institutional investors and hedge funds own 93.86% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on IONS. Bank of America raised their price objective on Ionis Pharmaceuticals from $86.00 to $97.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a research note on Wednesday, October 8th. Oppenheimer raised their price target on Ionis Pharmaceuticals from $84.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, October 8th. Morgan Stanley upped their price objective on Ionis Pharmaceuticals from $90.00 to $94.00 and gave the stock an “overweight” rating in a research note on Thursday, October 30th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and issued a $89.00 price objective (up previously from $85.00) on shares of Ionis Pharmaceuticals in a report on Thursday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Ionis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $87.05.

Insider Buying and Selling at Ionis Pharmaceuticals

In related news, EVP Holly B. Kordasiewicz sold 4,141 shares of the firm’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $75.66, for a total value of $313,308.06. Following the completion of the sale, the executive vice president owned 14,718 shares of the company’s stock, valued at $1,113,563.88. This trade represents a 21.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Eric Swayze sold 9,884 shares of the business’s stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $75.34, for a total transaction of $744,660.56. Following the completion of the transaction, the executive vice president owned 41,935 shares of the company’s stock, valued at $3,159,382.90. This trade represents a 19.07% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 391,163 shares of company stock valued at $30,183,387 over the last three months. Insiders own 2.71% of the company’s stock.

Ionis Pharmaceuticals Price Performance

Shares of IONS stock opened at $77.53 on Wednesday. Ionis Pharmaceuticals, Inc. has a 52 week low of $23.95 and a 52 week high of $86.15. The stock has a market capitalization of $12.56 billion, a PE ratio of -45.88 and a beta of 0.28. The company has a debt-to-equity ratio of 0.96, a quick ratio of 2.78 and a current ratio of 2.79. The stock’s fifty day moving average is $78.90 and its 200-day moving average is $64.33.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings results on Wednesday, October 29th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.35. Ionis Pharmaceuticals had a negative net margin of 26.45% and a negative return on equity of 44.26%. The business had revenue of $156.72 million for the quarter, compared to the consensus estimate of $131.75 million. During the same quarter in the prior year, the company earned ($0.95) EPS. The firm’s quarterly revenue was up 17.2% on a year-over-year basis. Equities research analysts expect that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current fiscal year.

Ionis Pharmaceuticals News Summary

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Analyst / media bullishness on olezarsen: A recent Seeking Alpha piece highlights an expected 2026 launch of olezarsen in SHTG and argues that approval/commercial rollout could drive a substantial revenue inflection for Ionis; the article notes strong recent momentum and positions olezarsen as the key upside catalyst. Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth
• Neutral Sentiment: Trading and technicals: Intraday volume is elevated (~4.9M shares vs. a ~1.5M average), suggesting the market is actively reacting to the news flow; the stock is above its 200‑day moving average (support) but near the 50‑day average—momentum could depend on upcoming clinical/commercial milestones.
• Negative Sentiment: Large, concentrated insider selling: Multiple executives (including CEO Brett P. Monia and several EVPs) sold shares on Jan 16 totaling roughly 117K shares (~$8.8M) — CEO sale (~44K shares, ~$3.3M) and several EVP sales of ~8–13K shares each. These filings can be reviewed in the SEC disclosures, which may signal tax/diversification activity but can also weigh on sentiment.
  Bennett filing
  Birchler filing
  Devers filing
  Hougen filing
  Jenne filing
  Kordasiewicz filing
  Monia (CEO) filing
  O’neil filing
  Schneider filing
  Swayze filings

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.